AVENUE THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
AVENUE THERAPEUTICS, INC. (ATXI) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$913.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-07
- AVENUE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$438.00K, a 148.24% decline year-over-year.
- AVENUE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $908.00K, a 35.65% decline year-over-year.
- AVENUE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $1.41M, a 7.66% decline year-over-year.
- AVENUE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $1.53M.
- AVENUE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $261.00K, a 67.82% decline from fiscal 2024.
- AVENUE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $811.00K.
- AVENUE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$4.92M, a 267.23% decline from fiscal 2022.
- AVENUE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $2.94M, a 366.72% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$913.00K 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | -$438.00K 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | $261.00K 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $1.11M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $732.00K 10-Q · filed 2026-08-07 | |||
| 2025-03-31 | $908.00K 10-Q · filed 2026-05-08 | |||
| 2024-12-31 | $811.00K 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $814.00K 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $3.14M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $1.41M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$4.92M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$6.55M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$5.14M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $1.53M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $2.94M 10-K · filed 2024-03-18 | |||
| 2022-09-30 | -$3.55M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$2.87M 10-Q · filed 2023-08-11 | |||
| 2022-03-31 | -$1.93M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $631.00K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$2.55M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$2.01M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$1.31M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | -$5.61M 10-K · filed 2022-03-25 | |||
| 2020-09-30 | -$4.42M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$3.49M 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | -$2.17M 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $6.07M 10-K · filed 2021-03-31 | |||
| 2019-09-30 | $6.07M 10-Q · filed 2020-11-04 | |||
| 2019-06-30 | $7.78M 10-Q · filed 2020-08-14 | |||
| 2019-03-31 | $26.78M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | -$9.11M 10-K · filed 2020-03-30 | |||
| 2018-09-30 | -$6.98M 10-Q · filed 2019-11-13 |